Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

IMPORTANCE: Immunomodulatory anticancer drugs, such as the anti–programmed death-1 drug pembrolizumab, have shown promising results in trials, and more patients will receive such treatments. Little is known about cutaneous adverse events (AEs) caused by these drugs and their possible correlation wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA Dermatol
Hauptverfasser: Sanlorenzo, Martina, Vujic, Igor, Daud, Adil, Algazi, Alain, Gubens, Matthew, Luna, Sara Alcántara, Lin, Kevin, Quaglino, Pietro, Rappersberger, Klemens, Ortiz-Urda, Susana
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5061067/
https://ncbi.nlm.nih.gov/pubmed/26222619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2015.1916
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge